Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Thalidomide may kill cancer cells by stopping the growth of new blood vessels to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients with HIV-associated Kaposi's sarcoma.

Key facts

Study ID

NCT00019123

Run by

National Cancer Institute (NCI)

Starts

1996-04-01

Expected to finish

2004-04-01

Last updated by the study team

2013-08-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Medicine Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.